Informed Consent in Clinical Studies in the Republic of Srpska

Snežana Pantović, Dijana Zrnić
{"title":"Informed Consent in Clinical Studies in the Republic of Srpska","authors":"Snežana Pantović, Dijana Zrnić","doi":"10.31743/recl.17188","DOIUrl":null,"url":null,"abstract":"As human medicine is developing at a galloping pace, continuously offering new medical products, diagnostic methods and preventive programmes, there is almost no time gap between their creation and application in medical practice. All these biomedical achievements are primarily intended to improve public health and the patient’s quality of life and health. Hence, it is important to define potential risks, side effects, and unwanted outcomes when applying a medical product/treatment before integrating it into healthcare. Unlike any other product/treatment intended for human use, medical products/treatments require prior clinical testing on human subjects (sick or sound). The authors of this paper have restricted their scientific interest to the participant (human subject) of a clinical study as one of the core elements of a clinical investigation, representing at the same time its means and its aim. By analyzing relevant international as well as national legal rules and ethical principles of the Republic of Srpska related to the participation of humans in clinical studies, it will be concluded that the participants’ safety and right to self-determination, integrity, and autonomy manifested through their independent right to either consent or refuse to participate in a clinical study supersedes the interests of science or society. However, clinical trial-related statistical data obtained from randomly chosen healthcare institutions in the Republic of Srpska will show certain derogations from prescribed ethical policies. Considering this fact, the authors have paid special attention to thematising the ethicality of recruiting participants for a clinical study based on partial or no information related to the purpose, methods, potential risks and side effects of the investigation in the name of the greater good for humanity. Such practice has accentuated the discretionary powers of ethical review committees on the one side and the uncertainty of the right to informed consent on the other.","PeriodicalId":337306,"journal":{"name":"Review of European and Comparative Law","volume":"144 7‐8","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2024-05-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Review of European and Comparative Law","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.31743/recl.17188","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

As human medicine is developing at a galloping pace, continuously offering new medical products, diagnostic methods and preventive programmes, there is almost no time gap between their creation and application in medical practice. All these biomedical achievements are primarily intended to improve public health and the patient’s quality of life and health. Hence, it is important to define potential risks, side effects, and unwanted outcomes when applying a medical product/treatment before integrating it into healthcare. Unlike any other product/treatment intended for human use, medical products/treatments require prior clinical testing on human subjects (sick or sound). The authors of this paper have restricted their scientific interest to the participant (human subject) of a clinical study as one of the core elements of a clinical investigation, representing at the same time its means and its aim. By analyzing relevant international as well as national legal rules and ethical principles of the Republic of Srpska related to the participation of humans in clinical studies, it will be concluded that the participants’ safety and right to self-determination, integrity, and autonomy manifested through their independent right to either consent or refuse to participate in a clinical study supersedes the interests of science or society. However, clinical trial-related statistical data obtained from randomly chosen healthcare institutions in the Republic of Srpska will show certain derogations from prescribed ethical policies. Considering this fact, the authors have paid special attention to thematising the ethicality of recruiting participants for a clinical study based on partial or no information related to the purpose, methods, potential risks and side effects of the investigation in the name of the greater good for humanity. Such practice has accentuated the discretionary powers of ethical review committees on the one side and the uncertainty of the right to informed consent on the other.
塞族共和国临床研究中的知情同意问题
随着人类医学的飞速发展,不断有新的医疗产品、诊断方法和预防方案问世,它们从诞生到应用于医疗实践之间几乎没有时间差。所有这些生物医学成果的主要目的都是为了改善公众健康,提高病人的生活质量和健康水平。因此,在将医疗产品/疗法应用于医疗保健之前,必须明确其潜在的风险、副作用和不希望出现的结果。与任何其他供人类使用的产品/治疗方法不同,医疗产品/治疗方法需要事先在人体(生病或健康)上进行临床试验。本文作者的科学兴趣仅限于临床研究的参与者(人体受试者),因为这是临床研究的核心要素之一,同时也是临床研究的手段和目的。通过分析与人类参与临床研究相关的国际和国内法律规则以及塞族共和国的伦理原则,我们将得出这样的结论:参与者的安全以及通过其同意或拒绝参与临床研究的独立权利所体现的自决、完整和自主权高于科学或社会的利益。然而,从塞族共和国随机选择的医疗机构获得的与临床试验相关的统计数据显示,规定的伦理政策存在某些偏差。考虑到这一事实,作者特别关注了以造福人类为名,在部分或完全不了解调查目的、方法、 潜在风险和副作用的基础上招募临床研究参与者的道德问题。这种做法一方面突出了伦理审查委员会的自由裁量权,另一方面也增加了知情同意权的不确定性。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信